Who Paid My Doc
Keith Flaherty
Boston, MA Medical Doctor
NPI 1861422966 CMS profile 130124
55 Fruit St, Lawrence House 202, Boston, MA 02114
General payments
$931,527
Research payments
$47,203
Ownership & investment interest
$0
Research they led as principal investigator
$1,324,629
Through program year 2025, Keith Flaherty of Boston, MA is reported in the CMS Open Payments database as having received $931,527 across 38 general payments and $47,203 in research payments paid to them. Separately, studies naming them as principal investigator received $1,324,629 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $3,200 | 1 | |
| 2024 | Research | $3,780 | 3 | |
| 2023 | Research | $9,270 | 7 | |
| 2022 | General | $48,750 | 3 | |
| 2022 | Research | $9,980 | 8 | |
| 2021 | General | $257,030 | 5 | |
| 2021 | Research | $9,190 | 8 | |
| 2020 | General | $256,334 | 8 | |
| 2020 | Research | $6,011 | 15 | |
| 2019 | General | $369,413 | 22 | |
| 2019 | Research | $5,773 | 9 |
Beside peers
- Keith Flaherty
- Massachusetts median
- Middle half of Massachusetts
- National median
In program year 2025, general payments to Keith Flaherty were reported at $0. Among 21,560 Massachusetts profiles paid that year, the median was $147 and the middle half received between $45 and $552.
Show as a table
| Year | Keith Flaherty | Massachusetts median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $369,413 | $133 | $40–$617 | $163 |
| 2020 | $256,334 | $105 | $32–$540 | $114 |
| 2021 | $257,030 | $124 | $35–$544 | $132 |
| 2022 | $48,750 | $126 | $40–$510 | $149 |
| 2023 | $0 | $144 | $47–$542 | $160 |
| 2024 | $0 | $144 | $45–$560 | $164 |
| 2025 | $0 | $147 | $45–$552 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
22
Drug cost
$350,277
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Braftovi Encorafenib | Brand | 11 | $176,807 | |
| Mektovi Binimetinib | Brand | 11 | $173,471 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$4,706
Medicare patients
28
Services billed
60
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 43% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
89 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.